27th Oct 2020 17:00
Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - Extends development agreement with "a leading global pharmaceutical company" to December 31. Deal, announced back in May 2018, sees Hemogenyx receive technical support to help develop and engineer antibodies. "As a result of the global crisis caused by the Covid-19 pandemic, the company has agreed with GlobalCo to a further extension of the Agreement until 31 December 2020 in order to properly complete the work required by both parties under the agreement."
Current stock price: 9.90 pence, down 19% on Tuesday
Year-to-date change: up sharply from 1.95p
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx